| 0.9532 -0.007 (-0.77%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.26 | 1-year : | 1.47 |
| Resists | First : | 1.08 | Second : | 1.25 |
| Pivot price | 0.91  |
|||
| Supports | First : | 0.8 | Second : | 0.66 |
| MAs | MA(5) : | 0.96 |
MA(20) : | 0.91 |
| MA(100) : | 1.3 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 52.5 |
D(3) : | 66.5 |
| RSI | RSI(14): 45.4 |
|||
| 52-week | High : | 6.65 | Low : | 0.8 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PRFX ] has closed below upper band by 31.7%. Bollinger Bands are 51.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.96 - 0.97 | 0.97 - 0.97 |
| Low: | 0.91 - 0.92 | 0.92 - 0.92 |
| Close: | 0.94 - 0.95 | 0.95 - 0.96 |
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
Fri, 05 Dec 2025
PainReform Ltd. (PRFX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Tue, 02 Dec 2025
PainReform (PRFX) Advances OcuRing-K Development for Improved Ca - GuruFocus
Tue, 02 Dec 2025
PainReform Commences Development for OcuRing™-K Phase II Trial, LayerBio’s Drop-Less Sustained-Release Ocular Therapy - Sahm
Tue, 02 Dec 2025
PainReform (Nasdaq: PRFX) moves OcuRing-K into Phase II plan in $9B cataract market - Stock Titan
Wed, 12 Nov 2025
PainReform’s DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset Analysis - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 4 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 4.8 (%) |
| Held by Institutions | 1.5 (%) |
| Shares Short | 205 (K) |
| Shares Short P.Month | 76 (K) |
| EPS | 29.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.19 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -36.2 % |
| Return on Equity (ttm) | -127.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | 0.03 |
| PEG Ratio | 0 |
| Price to Book value | 0.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|